menu
    • menu

    Company profile for Nurix Therapeutics

    NEW Drugs in Dev: 8
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents...
    Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents. Nurix was founded by a team of internationally renowned scientific experts in the E3 ubiquitin ligase regulation and structure field

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nurix TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1700 Owens Street, Suite 205 San Francisco, CA 94158
    Telephone
    Telephone
    415-660-5320
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nurixtx.com/contact/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Paris Packaging Week

    Paris Packaging Week

    Not Confirmed

    envelop Contact Supplier

    Paris Packaging Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nurix Therapeutics Reveals 2025 Financials And Corporate Update
    Nurix Therapeutics Reveals 2025 Financials And Corporate Update

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    Nurix Therapeutics Sets 2026 Goals For Advancing Bexobrutideg
    Nurix Therapeutics Sets 2026 Goals For Advancing Bexobrutideg

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216702/0/en/Nurix-Therapeutics-Outlines-2026-Goals-and-Objectives-for-Advancing-Bexobrutideg-and-Its-Pipeline-of-Novel-Degrader-Based-Medicines-in-Cancer-and-Autoimmune-Diseases.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Nurix Therapeutics Joins 44Th J.P. Morgan Healthcare Conference
    Nurix Therapeutics Joins 44Th J.P. Morgan Healthcare Conference

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212611/0/en/Nurix-Therapeutics-to-Participate-in-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Nurix Presents Bexobrutideg Data in Waldenström at ASH
    Nurix Presents Bexobrutideg Data in Waldenström at ASH

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201481/0/en/Nurix-Therapeutics-Presents-New-Data-from-the-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Waldenstr%C3%B6m-Macroglobulinemia-at-the-67th-American-Society-of-Hematology-ASH-Annual-Meeting-a.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Nurix Shows Strong Responses In Phase 1 Bexobrutideg Trial
    Nurix Shows Strong Responses In Phase 1 Bexobrutideg Trial

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/06/3201064/0/en/Nurix-Therapeutics-Presents-New-Data-Demonstrating-Durable-Deepening-Responses-in-Phase-1-Trial-of-Bexobrutideg-NX-5948-in-Patients-with-Relapsed-or-Refractory-Chronic-Lymphocytic-.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Nurix Therapeutics To Present Phase 1 Bexobrutideg Data At ASH
    Nurix Therapeutics To Present Phase 1 Bexobrutideg Data At ASH

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196838/0/en/Nurix-Therapeutics-Announces-Webcast-to-Review-New-and-Updated-Data-from-the-Phase-1-Clinical-Trial-of-BTK-Degrader-Bexobrutideg-NX-5948-To-Be-Presented-at-the-67th-American-Societ.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search